A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis

Journal of Translational Medicine

Demosthenes Bouros⁶  George Kolios²  Marios Froudarakis⁴  Antonis Antoniadis⁵  Dimitrios Gritzalis⁹  Brian Dardzinski⁸  Nikolaos Boussios¹  Athanassios Zissimopoulos¹  Anastasia Oikonomou⁷  Evangelos Bouros²  Paschalis Ntolios⁴  George Koliakos⁸  Vassilis Paspaliaris³  Argyris Tzouvelekis⁴ 

[1] Department of Nuclear Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece;Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece;Adistem Ltd., Wanchai, Hong Kong;Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece;Department of Pneumonology, General Hospital of Serres, Serres, Greece;Department of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis 68100, Greece;Department of Radiology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece;Biohellenika SA, Thessaloniki, Greece;Iaso General Hospital, Athens, Greece

关键词: Stromal vascular fraction;    Clinical trial;    Safety;    Idiopathic pulmonary fibrosis;    Mesenchymal stem cells;    Adipose derived stromal cells;   

Others  :  827171
DOI  :  10.1186/1479-5876-11-171

 received in 2013-03-23, accepted in 2013-07-10,  发布年份 2013

【 摘 要 】

Introduction

Regenerative medicine and particular adult stem cells represent an alternative option with several fruitful therapeutic applications in patients suffering from chronic lung diseases including idiopathic pulmonary fibrosis (IPF). Nevertheless, lack of knowledge regarding the origin and the potential of mesenchymal stem cells (MSCs) to differentiate into fibroblasts has limited their use for the treatment of this dismal disease.

Patients and methods

To this end, we conducted a phase Ib, non-randomized, clinical trial to study the safety of three endobronchial infusions of autologous adipose derived stromal cells (ADSCs)-stromal vascular fraction (SVF) (0.5 million cells per kgr of body weight per infusion) in patients with IPF (n=14) of mild to moderate disease severity (forced vital capacity –FVC>50% predicted value and diffusion lung capacity for carbon monoxide-DL_CO>35% of predicted value). Our primary end-point was incidence of treatment emergent adverse events within 12 months. Alterations of functional, exercise capacity and quality of life parameters at serial time points (baseline, 6 and 12 months after first infusion) were exploratory secondary end-points.

Results

No cases of serious or clinically meaningful adverse events including short-term infusional toxicities as well as long-term ectopic tissue formation were recorded in all patients. Detailed safety monitoring through several time-points indicated that cell-treated patients did not deteriorate in both functional parameters and indicators of quality of life.

Conclusions

The clinical trial met its primary objective demonstrating an acceptable safety profile of endobronchially administered autologous ADSCs-SVF. Our findings accelerate the rapidly expanded scientific knowledge and indicate a way towards future efficacy trials.

【 授权许可】

   
2013 Tzouvelekis et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Wuyts WA, Agostini C, Antoniou K, Bouros D, Chambers R, Cottin V, et al.: The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J 2013, 41:1207-1218.
• [2]Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al.: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
• [3]Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al.: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769.
• [4]Bouros D: Pirfenidone for idiopathic pulmonary fibrosis. Lancet 2011, 377:1727-1729.
• [5]Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al.: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365:1079-1087.
• [6]Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G: Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174:810-816.
• [7]Raghu G: Improving the standard of care for patients with idiopathic pulmonary fibrosis requires participation in clinical trials. Chest 2009, 136:330-333.
• [8]Garcia-Gomez I, Elvira G, Zapata AG, Lamana ML, Ramirez M, Castro JG, et al.: Mesenchymal stem cells: biological properties and clinical applications. Expert Opin Biol Ther 2010, 10:1453-1468.
• [9]Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH: New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm Res 2007, 24:819-841.
• [10]Kajstura J, Rota M, Hall SR, Hosoda T, D’Amario D, Sanada F, et al.: Evidence for human lung stem cells. N Engl J Med 2011, 364:1795-1806.
• [11]Moodley Y, Manuelpillai U, Weiss DJ: Cellular therapies for lung disease: a distant horizon. Respirology 2011, 16:223-237.
• [12]Tzouvelekis A, Antoniadis A, Bouros D: Stem cell therapy in pulmonary fibrosis. Curr Opin Pulm Med 2011, 17:368-373.
• [13]Tzouvelekis A, Koliakos G, Ntolios P, Baira I, Bouros E, Oikonomou A, et al.: Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. J Transl Med 2011, 9:182. BioMed Central Full Text
• [14]Tzouvelekis A, Laurent G, Bouros D: Stem cell therapy in chronic obstructive pulmonary disease. Seeking the prometheus effect. Curr Drug Targets 2013, 14:246-252.
• [15]Weiss DJ, Bertoncello I, Borok Z, Kim C, Panoskaltsis-Mortari A, Reynolds S, et al.: Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 2011, 8:223-272.
• [16]Toonkel RL, Hare JM, Matthay MA, Glassberg MK: Mesenchymal stem cells and idiopathic pulmonary fibrosis: potential for clinical testing. Am J Respir Crit Care Med 2013. [Epub ahead of print]
• [17]Wang XX, Zhang FR, Shang YP, Zhu JH, Xie XD, Tao QM, et al.: Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 2007, 49:1566-1571.
• [18]Zeng C, Wang X, Hu X, Chen J, Wang L: Autologous endothelial progenitor cells transplantation for the therapy of primary pulmonary hypertension. Med Hypotheses 2007, 68:1292-1295.
• [19]Tzouvelekis A, Ntolios P, Bouros D: Stem cell treatment for chronic lung diseases. Respiration 2013, 85:179-192.
• [20]Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, et al.: Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy 2013, 15:641-648.
• [21]Astori G, Vignati F, Bardelli S, Tubio M, Gola M, Albertini V, et al.: “In vitro” and multicolor phenotypic characterization of cell subpopulations identified in fresh human adipose tissue stromal vascular fraction and in the derived mesenchymal stem cells. J Transl Med 2007, 5:55. BioMed Central Full Text
• [22]Casteilla L, Planat-Benard V, Laharrague P, Cousin B: Adipose-derived stromal cells: Their identity and uses in clinical trials, an update. World J Stem Cells 2011, 3:25-33.
• [23]Casteilla L, Planat-Benard V, Bourin P, Laharrague P: Cousin B: [Use of adipose tissue in regenerative medicine]. Transfus Clin Biol 2011, 18:124-128.
• [24]Casteilla L, Planat-Benard V, Dehez S, De BS, Barreau C, Andre M: Endothelial and cardiac regeneration from adipose tissues. Methods Mol Biol 2011, 702:269-287.
• [25]Gimble JM, Guilak F, Bunnell BA: Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells. Stem Cell Res Ther 2010, 1:19. BioMed Central Full Text
• [26]Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al.: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002, 13:4279-4295.
• [27]Mitchell JB, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, et al.: Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells 2006, 24:376-385.
• [28]Katsha AM, Ohkouchi S, Xin H, Kanehira M, Sun R, Nukiwa T, et al.: Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol Ther 2011, 19:196-203.
• [29]Schweitzer KS, Johnstone BH, Garrison J, Rush NI, Cooper S, Traktuev DO, et al.: Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking. Am J Respir Crit Care Med 2011, 183:215-225.
• [30]Sueblinvong V, Loi R, Eisenhauer PL, Bernstein IM, Suratt BT, Spees JL, et al.: Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells. Am J Respir Crit Care Med 2008, 177:701-711.
• [31]Zhen G, Liu H, Gu N, Zhang H, Xu Y, Zhang Z: Mesenchymal stem cells transplantation protects against rat pulmonary emphysema. Front Biosci 2008, 13:3415-3422.
• [32]Zhen G, Xue Z, Zhao J, Gu N, Tang Z, Xu Y, et al.: Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells. Cytotherapy 2010, 12:605-614.
• [33]Aguilar S, Scotton CJ, McNulty K, Nye E, Stamp G, Laurent G, et al.: Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One 2009, 4:e8013.
• [34]Kumamoto M, Nishiwaki T, Matsuo N, Kimura H, Matsushima K: Minimally cultured bone marrow mesenchymal stem cells ameliorate fibrotic lung injury. Eur Respir J 2009, 34:740-748.
• [35]Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S, et al.: Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol 2009, 175:303-313.
• [36]Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, et al.: Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003, 100:8407-8411.
• [37]Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, et al.: Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005, 33:145-152.
• [38]Shigemura N, Okumura M, Mizuno S, Imanishi Y, Matsuyama A, Shiono H, et al.: Lung tissue engineering technique with adipose stromal cells improves surgical outcome for pulmonary emphysema. Am J Respir Crit Care Med 2006, 174:1199-1205.
• [39]Shigemura N, Okumura M, Mizuno S, Imanishi Y, Nakamura T, Sawa Y: Autologous transplantation of adipose tissue-derived stromal cells ameliorates pulmonary emphysema. Am J Transplant 2006, 6:2592-2600.
• [40]Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al.: A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54:2277-2286.
• [41]Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, et al.: Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012, 308:2369-2379.
• [42]Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, et al.: LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J 2010, 37:412-420.
• [43]Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, et al.: Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 2011, 306:2110-2119.
• [44]Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, et al.: Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA 2012, 308:2380-2389.
• [45]King A: Stem cells. Could it be TIME to abandon BMCs? Nat Rev Cardiol 2013, 10:8.
• [46]Ribeiro-Paes JT, Bilaqui A, Greco OT, Ruiz MA, Marcelino MY, Stessuk T, et al.: Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema. Int J Chron Obstruct Pulmon Dis 2011, 6:63-71.
• [47]Weiss DJ, Casaburi R, Flannery R, Leroux-Williams M, Tashkin DP: A placebo-controlled randomized trial of mesenchymal stem cells in chronic obstructive pulmonary disease. Chest 2013, 143:1590-1598.
• [48]Tzouvelekis A, Paspaliaris V, Koliakos G, Ntolios P, Oikonomou A, Froudarakis M, et al.: A prospective, non randomized, clinical trial to study the safety and efficacy of the endobronchial autologous infusion of adipose-derived mesenchymal stem cells (ADMSCs) in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2011., 176(3) Ref Type: Abstract
• [49]De Vos RJ, Weir A, Van Schie HT, Bierma-Zeinstra SM, Verhaar JA, Weinans H, et al.: Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA 2010, 303:144-149.
• [50]Zurita M, Otero L, Aguayo C, Bonilla C, Ferreira E, Parajon A, et al.: Cell therapy for spinal cord repair: optimization of biologic scaffolds for survival and neural differentiation of human bone marrow stromal cells. Cytotherapy 2010, 12:522-537.
• [51]Lin F, Josephs SF, Alexandrescu DT, Ramos F, Bogin V, Gammill V, et al.: Lasers, stem cells, and COPD. J Transl Med 2010, 8:16. BioMed Central Full Text
• [52]Dominici M, Le BK, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al.: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
• [53]Werner J, Dragotakes SC, Fernandez-del CC, Rivera JA, Ou J, Rattner DW, et al.: Technetium-99m-labeled white blood cells: a new method to define the local and systemic role of leukocytes in acute experimental pancreatitis. Ann Surg 1998, 227:86-94.
• [54]Folgiero V, Migliano E, Tedesco M, Iacovelli S, Bon G, Torre ML, et al.: Purification and characterization of adipose-derived stem cells from patients with lipoaspirate transplant. Cell Transplant 2010, 19:1225-1235.
• [55]Krause A, Hohberg B, Heine F, John M, Burmester GR, Witt C: Cytokines derived from alveolar macrophages induce fever after bronchoscopy and bronchoalveolar lavage. Am J Respir Crit Care Med 1997, 155:1793-1797.
• [56]Perin EC, Silva GV, Henry TD, Cabreira-Hansen MG, Moore WH, Coulter SA, et al.: A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J 2011, 161:1078-1087.
• [57]Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, et al.: Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012, 307:1717-1726.
• [58]Wolf D, Wolf AM: Mesenchymal stem cells as cellular immunosuppressants. Lancet 2008, 371:1553-1554.
• [59]Zhao F, Zhang YF, Liu YG, Zhou JJ, Li ZK, Wu CG, et al.: Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplant Proc 2008, 40:1700-1705.
• [60]Alt EU, Senst C, Murthy SN, Slakey DP, Dupin CL, Chaffin AE, et al.: Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res 2012, 8:215-225.
• [61]Masato U, Akira N, Tatsuo N: Intravenous administration of adipose-derived stromal cells does not ameliorate bleomycin-induced lung injury in rats. Open J Regen Med 2013, 2(2):39-45.
• [62]Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, et al.: Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003, 108:863-868.
• [63]Weiss DJ, Kolls JK, Ortiz LA, Panoskaltsis-Mortari A, Prockop DJ: Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 2008, 5:637-667.
• [64]Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, et al.: Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 179:588-594.
• [65]Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski JM, et al.: Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol 2007, 179:2592-2599.
• [66]Feghali-Bostwick CA, Wilkes DS: Autoimmunity in idiopathic pulmonary fibrosis: are circulating autoantibodies pathogenic or epiphenomena? Am J Respir Crit Care Med 2011, 183:692-693.
• [67]Kotsianidis I, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropoulos P, et al.: Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 179:1121-1130.
• [68]Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D: Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.